Health Economic Analyses of the Justice Community Opioid Innovation Network (JCOIN)

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2021 Jan 9

PMID 33419602

Citations 4

Authors

Sean M Murphy

Neda Laiteerapong

Mai T Pho

Danielle Ryan

Ivan Montoya

Theresa I Shireman

Elbert Huang

Kathryn E McCollister

Affiliations

Soon will be listed here.

Abstract

The Justice Community Opioid Innovation Network (JCOIN) will generate real-world evidence to address the unique needs of people with opioid use disorder (OUD) in justice settings. Evidence regarding the economic value of OUD interventions in justice populations is limited. Moreover, the variation in economic study designs is a barrier to defining specific interventions as broadly cost-effective. The JCOIN Health Economics Analytic Team (HEAT) has worked closely with the Measures Committee to incorporate common economic measures and instruments across JCOIN studies, which will: a) ensure rigorous economic evaluations within each trial; b) enhance comparability of findings across studies; and c) allow for cross-study analyses of trials with similar designs/settings (e.g., pre-reentry MOUD), to assess questions beyond the scope of a single study, while controlling for and evaluating the effect of intervention-, organizational-, and population-level characteristics. We describe shared trial characteristics relevant to the economic evaluations, and discuss potential cross-study economic analyses.

Citing Articles

Cost analysis of MOUD implementation and sustainability in Massachusetts jails.

Ryan D, Ekanayake D, Evans E, Hayes E, Senst T, Friedmann P Health Justice. 2025; 13(1):9.

PMID: 39907840 PMC: 11796061. DOI: 10.1186/s40352-025-00321-z.

Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies.

Jalali A Expert Rev Pharmacoecon Outcomes Res. 2024; 24(5):599-611.

PMID: 38696161 PMC: 11389975. DOI: 10.1080/14737167.2024.2350561.

Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.

Ryan D, Montoya I, Koutoujian P, Siddiqi K, Hayes E, Jeng P J Subst Use Addict Treat. 2023; 146:208943.

PMID: 36880906 PMC: 10084043. DOI: 10.1016/j.josat.2022.208943.

NIH HEAL Clinical Data Elements (CDE) implementation: NIH HEAL Initiative IMPOWR network IDEA-CC.

Adams M, Hurley R, Siddons A, Topaloglu U, Wandner L Pain Med. 2023; 24(7):743-749.

PMID: 36799548 PMC: 10321760. DOI: 10.1093/pm/pnad018.

Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Morgan J, Walley A, Murphy S, Chatterjee A, Hadland S, Barocas J Drug Alcohol Depend. 2021; 225:108764.

PMID: 34051547 PMC: 8488795. DOI: 10.1016/j.drugalcdep.2021.108764.

References

Jalali A, Ryan D, McCollister K, Marsch L, Schackman B, Murphy S . Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. J Subst Abuse Treat. 2020; 112S:18-27. PMC: 7293894. DOI: 10.1016/j.jsat.2020.02.002. View

Martin R, Stein L, Rohsenow D, Belenko S, Hurley L, Clarke J . Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol. J Subst Abuse Treat. 2021; 128:108364. PMC: 8384642. DOI: 10.1016/j.jsat.2021.108364. View

Eddie D, Hoffman L, Vilsaint C, Abry A, Bergman B, Hoeppner B . Lived Experience in New Models of Care for Substance Use Disorder: A Systematic Review of Peer Recovery Support Services and Recovery Coaching. Front Psychol. 2019; 10:1052. PMC: 6585590. DOI: 10.3389/fpsyg.2019.01052. View

Jansson I, Hesse M, Fridell M . Validity of self-reported criminal justice system involvement in substance abusing women at five-year follow-up. BMC Psychiatry. 2008; 8:2. PMC: 2265279. DOI: 10.1186/1471-244X-8-2. View

Murphy S, Jeng P, Poole S, Jalali A, Vocci F, Gordon M . Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Pract. 2020; 15(1):15. PMC: 7178627. DOI: 10.1186/s13722-020-00188-5. View

Scott C, Dennis M, Grella C, Watson D . Improving retention across the OUD service cascade upon reentry from jail using Recovery Management Checkups-Adaptive (RMC-A) experiment. J Subst Abuse Treat. 2021; 128:108245. PMC: 8192586. DOI: 10.1016/j.jsat.2020.108245. View

Sordo L, Barrio G, Bravo M, Indave B, Degenhardt L, Wiessing L . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357:j1550. PMC: 5421454. DOI: 10.1136/bmj.j1550. View

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D . Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16(2):231-50. DOI: 10.1016/j.jval.2013.02.002. View

Howell B, Puglisi L, Clark K, Albizu-Garcia C, Ashkin E, Booth T . The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from.... J Subst Abuse Treat. 2021; 128:108315. PMC: 8319218. DOI: 10.1016/j.jsat.2021.108315. View

10.

Krawczyk N, Picher C, Feder K, Saloner B . Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. Health Aff (Millwood). 2017; 36(12):2046-2053. PMC: 6035729. DOI: 10.1377/hlthaff.2017.0890. View

11.

Waddell E, Springer S, Marsch L, Farabee D, Schwartz R, Nyaku A . Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abuse Treat. 2021; 128:108389. PMC: 8384640. DOI: 10.1016/j.jsat.2021.108389. View

12.

Roberts R, Bergstralh E, Schmidt L, Jacobsen S . Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol. 1996; 49(9):989-95. DOI: 10.1016/0895-4356(96)00143-6. View

13.

Knight D, Becan J, Olson D, Davis N, Jones J, Wiese A . Justice community opioid innovation network (JCOIN): The TCU research hub. J Subst Abuse Treat. 2021; 128:108290. DOI: 10.1016/j.jsat.2021.108290. View

14.

McCollister K, French M, Fang H . The cost of crime to society: new crime-specific estimates for policy and program evaluation. Drug Alcohol Depend. 2010; 108(1-2):98-109. PMC: 2835847. DOI: 10.1016/j.drugalcdep.2009.12.002. View

15.

Blanco C, Volkow N . Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019; 393(10182):1760-1772. DOI: 10.1016/S0140-6736(18)33078-2. View

16.

Elkington K, Nunes E, Schachar A, Ryan M, Garcia A, Van DeVelde K . Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults. J Subst Abuse Treat. 2021; 128:108277. PMC: 8491168. DOI: 10.1016/j.jsat.2021.108277. View

17.

Brown J, Adams M . Patients as reliable reporters of medical care process. Recall of ambulatory encounter events. Med Care. 1992; 30(5):400-11. DOI: 10.1097/00005650-199205000-00003. View

18.

Harlow S, Linet M . Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol. 1989; 129(2):233-48. DOI: 10.1093/oxfordjournals.aje.a115129. View

19.

Saldana L, Chamberlain P, Bradford W, Campbell M, Landsverk J . The Cost of Implementing New Strategies (COINS): A Method for Mapping Implementation Resources Using the Stages of Implementation Completion. Child Youth Serv Rev. 2014; 39:177-182. PMC: 3979632. DOI: 10.1016/j.childyouth.2013.10.006. View

20.

Evans E, Stopka T, Pivovarova E, Murphy S, Taxman F, Ferguson W . Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021; 128:108275. PMC: 8263807. DOI: 10.1016/j.jsat.2021.108275. View